Map17, a ROS-dependent oncogene
MAP17 is a small 17 kDa non-glycosylated membrane protein previously identified as being overexpressed in carcinomas. Breast tumor cells that overexpress MAP17 show an increased tumoral phenotype with enhanced proliferative capabilities both in the presence or the absence of contact inhibition, decr...
Main Author: | Amancio eCarnero |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2012-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2012.00112/full |
Similar Items
-
Independent Negative Prognostic Role of TCF1 Expression within the Wnt/β-Catenin Signaling Pathway in Primary Breast Cancer Patients
by: Concetta Saponaro, et al.
Published: (2019-07-01) -
Dr. Jekyll and Mr. Hyde: MAP17’s up-regulation, a crosspoint in cancer and inflammatory diseases
by: José M. García-Heredia, et al.
Published: (2018-04-01) -
NHERF1 Enhances Cisplatin Sensitivity in Human Cervical Cancer Cells
by: Tao Tao, et al.
Published: (2017-01-01) -
Alteration in the sensitivity to crizotinib by Na+/H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers
by: Fenglian Yang, et al.
Published: (2020-03-01) -
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
by: Xuan Wei, et al.
Published: (2021-03-01)